Funded Startups in Beverly
Beverly, Massachusetts has produced a cluster of funded companies concentrated almost entirely within life sciences, with biotechnology accounting for seve…
Beverly, Massachusetts has produced a cluster of funded companies concentrated almost entirely within life sciences, with biotechnology accounting for seven of the twelve most recent rounds shown. The largest close in this set is Nth Cycle's $37M Series B in December 2023 — a consumer electronics and materials recovery play — followed by BioVie's $12M Series Unknown round in August 2025, the most recent funding event in the data. BioVie also raised $3M in September 2024, making it one of the few repeat fundings visible here.
Most rounds carry a "Series Unknown" classification, which limits stage visibility across the segment. Deal sizes outside Nth Cycle are modest: Endolytix and Akston Biosciences each closed at $5M, while Prospective Research, New Frontier Bio, and LeviSense Medical raised between $200K and $310K. Non-biotech representation includes Radical Plastics (manufacturing), Fluid-Screen (data and analytics), and 3EO Health (public health), though the dominant pattern is early-stage biotech capital at sub-$10M check sizes.
Most recent rounds
12 shownRelated listings
Frequently asked
What is the largest disclosed round among recent Beverly fundings?
Nth Cycle's Series B in December 2023 at $37M is the largest disclosed round in this set, standing well above the next-largest, BioVie's $12M Series Unknown close in August 2025. Most other rounds in this group fall below $6M.
Which sector accounts for most of Beverly's recent funding activity?
Biotechnology dominates, with seven of the twelve companies — BioVie, Endolytix, New Frontier Bio, seqWell, Prospective Research, Akston Biosciences, and a second BioVie round — all classified under that sector. The remainder span manufacturing, consumer electronics, public health, data analytics, and health care.
How many Beverly companies have raised more than once in this dataset?
BioVie appears twice, with a $3M close in September 2024 followed by a $12M close in August 2025, suggesting active follow-on activity within a 12-month window.
What round stages are most common in this Beverly funding list?
The majority of rounds are classified as Series Unknown or Venture - Series Unknown, making stage visibility limited across this set. The only clearly staged rounds are Nth Cycle's Series B ($37M), Fluid-Screen's Series A ($1M), LeviSense Medical's Seed ($300K), and Prospective Research's Debt Financing ($200K).
What is the typical deal size for Beverly startups in this dataset?
Excluding Nth Cycle's outlier $37M Series B, disclosed amounts range from $200K (Prospective Research) to $12M (BioVie's August 2025 round), with several clustered between $300K and $5M. One round from 3EO Health lists an undisclosed amount.
Does Beverly's funded startup activity show any recent acceleration?
The most recent close in the dataset is BioVie's $12M round dated August 7, 2025, with activity present in each year from 2022 through 2025. The 2023–2024 period accounts for six of the twelve rounds shown, including the largest single close.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.